Long-Acting Dihydropyridine Calcium Antagonists. 4. Synthesis and Structure-Activity Relationships for a Series of Basic and Nonbasic Derivatives of 2-[(2-Aminoethoxy)methyl]-1,4-dihydropyridine Calcium Antagonists

David Alker,^{*,†} Simon F. Campbell,[†] Peter E. Cross,[†] Roger A. Burges,[‡] Anthony J. Carter,[‡] and Donald G. Gardiner[‡]

Pfizer Central Research, Sandwich, Kent CT13 9NJ, United Kingdom. Received May 1, 1989

The preparation of a series of 1,4-dihydropyridines (DHPs) which have polar, acyclic, nonbasic substituents on an ethoxymethyl chain at the 2-position is described. In addition, in order to assess the effects of incorporating a basic center into DHPs of this type, a series of glycinamides were also prepared. The calcium antagonist activity on rat aorta of both these classes of DHP is compared with their negative inotropic activity as determined by using a Langendorff perfused guinea pig heart model. A number of the compounds evaluated have activity of the same order as nifedipine although those with more extended substituents have lower potency, particularly when a basic substituent is present. The compounds examined displayed a wide variation in selectivity for vascular over cardiac tissue. A number of structure-activity relationship trends were identified and possible explanations to account for the differences in selectivity observed are advanced. One of the compounds, 2-[[2-[[4-(2-chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyrid-2-yl]methoxylethyl]amino]acetamide (26, UK-51,656), was identified as a potent (IC₅₀ = 4 × 10⁻⁹ M) calcium antagonist which is 20-fold selective for vascular over cardiac tissue and which has a markedly longer duration of action (>5 h) than nifedipine in the anesthetized dog on intravenous administration. The pharmacokinetic half-life of 26 was established as 4.7 h and possible explanations are advanced to account for 26 having a shorter plasma half-life than amlodipine and a longer plasma half-life than felodipine.

Calcium antagonists are a well-established therapeutic class of agents which are finding increasing use in the treatment of angina and hypertension. One of the major structural series with this mode of action is the 1,4-dihydropyridines (DHPs). We have recently reported¹ the synthesis and structure-activity relationships (SARs) of a series of DHP calcium antagonists which have a basic side chain linked to the 2-position of the DHP ring. From this work we identified amlodipine (1), a compound with



[†]Department of Chemistry. [‡]Department of Biology. improved bioavailability and duration of action over currently available calcium antagonists. Amlodipine is now in late-stage clinical development as a once-daily treatment for angina^{2,3} and hypertension.^{4,5} Subsequent work established that the basic center in amlodipine was not an absolute requirement for calcium antagonist activity and that the amino function could be replaced by polar heterocycles as in 2^6 and $3.^7$ The much higher potency of 2 and 3 for vascular rather than cardiac tissue was thought to arise from favorable hydrogen-bonding interactions between the nonbasic polar heterocyclic group on the side chain on the 2-position and the DHP receptor. In order to establish whether structural modification of 2 and 3 was consistent with calcium antagonist activity, we decided to investigate DHPs (I) containing acyclic, polar functionality



I: X = C - O, SO₂, C N(CN); R = alkyl, heterocyclyl; NH-alkyl, NH-heterocyclyl



II: R^1 , $R^2 = H$, CH_3 ; $R^3 = H$, alkyl

- Arrowsmith, J. E.; Campbell, S. F.; Cross, P. E.; Stubbs, J. K.; Burges, R. A.; Gardiner, D. G.; Blackburn, K. J. J. Med. Chem. 1986, 29, 1696.
- (2) Glasser, S. P.; West, T. W. Am. J. Cardiol. 1988, 62, 518.
- (3) Kinnard, D. R.; Harris, M.; Hossack, K. F. J. Am. Coll. Cardiol. 1988, 12, 791.
- (4) Webster, J.; Robb, O. J.; Jeffers, T. A.; Scott, A. K.; Petrie, J. C.; Towler, H. M. Br. J. Clin. Pharmacol. 1987, 24, 713.
- (5) Julius, S. J. Cardiovasc. Pharmacol. 1988, 12, Suppl. 7, S27.
- (6) Arrowsmith, J. E.; Campbell, S. F.; Cross, P. E.; Burges, R. A.; Gardiner, D. G. J. Med. Chem. 1989, 32, 562.
- (7) Alker, D.; Campbell, S. F.; Cross, P. E.; Burges, R. A.; Carter, A. J.; Gardiner, D. G. J. Med. Chem. 1989, 32, 2381.

also capable of hydrogen-bonding to the DHP receptor. The effect of combining basic and nonbasic functionality in the 2-position of the DHP ring was probed by synthesizing a series of hybrid structures (II). It was expected that the favorable pharmacokinetics displayed by amlodipine might also be expressed in this series.

Chemistry

The synthesis of the DHP derivatives 4-23 was achieved by the transformations shown in Scheme I. Acetylation of 1 gave 4 (route A) while 5-7 were prepared by using a peptide-coupling procedure⁸ involving 1-hydroxybenzotriazole hydrate, 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride, and 4-methylmorpholine (route B). Reaction of 1 or 8 with isocyanates gave 9-11 (route C) while the more complex ureas (13-16) were synthesized in good yield by a two-step procedure (route D). Thus, reaction of 1 with CDI gave [(1-imidazolyl)carbonyl]amino derivative 12 as a stable, isolable solid which could be transformed smoothly into ureas 13-16 by treatment with the appropriate primary amines. This method represents a convenient means of preparing unsymmetrical ureas containing functionality which is not compatible with an isocvanate or carbamovl chloride intermediate, e.g. 13. Sulfamoylamino analogues 17 and 18 were obtained by heating 1 and 8, respectively, with sulfamide in dioxane (route E) while the cyanoguanidines 21-23 were prepared in a two-step sequence via 19 or 20 (route F) as outlined in a previous paper of this series.⁶

The preparation of 24-33 was accomplished by the routes summarized in Scheme II. Alkylation of 1 with 1 equiv of methyl bromoacetate gave approximately equal amounts of the mono- (24) and bis-alkylated (25) products, which were readily separable by chromatography. Reaction of 24 and 25 with concentrated aqueous ammonia afforded 26 and 27, respectively. Alternatively, direct alkylation of 1 with 1.1 equiv of 2-chloroacetamide in refluxing acetonitrile resulted in a modest yield of 26, together with 27, which could be separated by chromatography. Bis-alkylated product 27 was obtained more efficiently by heating 1 with 2.7 equiv of 2-chloroacetamide in DMF at 110–120 °C. Stirring 24 with the appropriate primary amine led to 28-30. Alkylation of 1 with ethyl 2-bromopropionate gave 31 (a small amount of a second product, observed by TLC but not isolated, was presumed to be bis-alkylated material), which on reaction with concentrated aqueous ammonia gave 32 (as a mixture of diastereomers). Compound 33 was formed in poor yield by heating 1 with 2-bromo-2-methylpropionamide.⁹

Results and Discussion

In vitro calcium antagonist activity (expressed as an IC_{50}) was assessed as the concentration of the compound required to inhibit the calcium-induced contraction of potassium-depolarized rat aorta by 50%. Negative inotropy (expressed as an IC_{26}) was determined in vitro using a Langendorff perfused guinea pig heart preparation. An examination of the data for compounds 4–23 suggests that the DHP receptor can accommodate DHPs with a range of substituents in the 2-position without marked adverse effects on activity (see Table I). For example there is only a 5-fold difference in in vitro activity within the wide range of structural prototypes 4, 9, 17, and 21. However, certain SAR trends are apparent from the data. In ureas 9, 11, and 13–16, greatest potency is seen for 9, which has the smallest N3 substituent, whereas larger groups as in 11,

Scheme I^{a,b}

route A

ь

route C

route D

DHP-NHR

8: R = CH₂

1: R = H

DHP-NRSO₂NH₂

18: R = CH3

17: R = H

DHP-NHCOCH₃

4

DHP-NHCOR

DHP-NRCONHR

11: R = H; $R^1 = CH_2CO_2Et$

9: R = H; $R^1 = CH_3$

10: $R = R^{1} = CH_{3}$

$$R = CH_2CH_2NH_2$$
 14: $R = CH_2CONH_2$

16: R = CH

route F

DHP-NHR
$$g$$
 DHP-NR SMe e
1: R = H 19: R = H
8: R = CH₃ 20: R = CH₃

12

13

DHP-NHR

1: R = H

8: R = CH3

DHP-NR¹ 21: R = H; $R^1 = CH_3$ 22: $R = R^1 = CH_3$ 23: R = H; $R^1 = CH_2CH_2NMe_2$

^aReagents: (a) CH₃COCl, pyridine; (b) 1-hydroxybenzotriazole hydrate, 4-methylmorpholine, $Me_2N(CH_2)_3N=C=NEt$ HCl, RCO₂H; (c) RNCO; (d) CDI, 4-methylmorpholine; (e) RNH₂; (f) NH₂SO₂NH₂; (g) (MeS)₂C=NCN.



14, and 16 lead to lower activity. The comparable activity seen for 11, 14, and 16, which have structurally diverse N3 substituents, confirms the tolerance of the DHP receptor to structural variation in the 2-position of the DHP ring.

Urea derivatives 13 and 15, where the N3 substituent contains a basic center or is a heterocycle, respectively, are both markedly less active. The detrimental effect of introducing a substituent containing a basic center is also seen by comparing cyanoguanidines 21 and 23. This is in contrast to amlodipine, where the presence of a basic

⁽⁸⁾ Sheehan, J. C.; Cruickshank, P. A.; Boshart, G. L. J. Org. Chem. 1961, 26, 2525.

⁽⁹⁾ Bischoff, C. A. Chem. Ber. 1897, 30, 2310.

Table I. Data for Compounds Used i	in Study
------------------------------------	----------

no	route	mn °C	recryst ⁿ	formula	77 mald	Ca	inotropy	selectivity
110.	Toute	mp, c	sorvent	Iormula	% yield	p10 ₅₀ -	p1025°	index
4	1A	97-99	Et_2O	$C_{22}H_{27}ClN_2O_6$	75	7.8 ^d	7.6	1.6
5	1 B	81-84	Et_2O	$C_{26}H_{28}ClN_3O_6$	57	7.8	7.6	1.6
6	1B	117-118	Et_2O	$C_{25}H_{27}ClN_4O_6$	42	7.4	7.5	0.8
7	1 B	125-130 dec	Et_2O	$C_{26}H_{28}ClN_3O_7$	63	8.2	7.0	16
9	1C	75–90 dec	Et_2O	$C_{22}H_{28}ClN_3O_6$	85	8.5	7.6	13
10	1C	160 - 162	$EtOAc/Et_2O$	$C_{23}H_{30}ClN_3O_6$	53	7.7	7.0	5
11	1C	125 - 127	EtOAc/hexane	$C_{25}H_{32}ClN_3O_8$	41	8.0	7.0	10
13	1D	90 dec	EtOAc/EtOH	$C_{23}H_{31}CIN_4O_6 \cdot C_4H_4O_4$	58	7.3	7.1	1.6
14	$1\mathbf{D}$	114-116	EtOAc	$C_{23}H_{29}ClN_4O_7$	23	7.7	6.4	20
15	1D	140-143	EtOAc	$C_{25}H_{28}CIN_5O_7H_2O$	16	6.8	7.7	0.1
16	1D	75-77	EtOAc	$C_{26}H_{34}ClN_5O_7$	32	7.8	6.2	40
17	$1\mathbf{E}$	150 - 152	Et_2O	$C_{20}H_{26}CIN_3O_7S$	77	8.1	7.1	10
18	$1\mathbf{E}$	117-120	Et_2O	$C_{21}H_{28}CIN_3O_7S$	88	7.6	6.7	8
21	$1\mathbf{F}$	188-190	EtOH	$C_{23}H_{28}ClN_5O_5$	64	8.2	7.5	5
22	$1\mathbf{F}$	131-136	Et_2O	$C_{24}H_{30}CIN_5O_5$	74	7.6	6.6	10
23	$1\mathbf{F}$	202-204 dec	EtOAc	$C_{26}H_{35}CIN_6O_5$	79	7.3	6.8	3
26	2	136-138	EtOAc	$C_{22}H_{28}CIN_3O_6$	31°/62 ^f	8.4	7.1	20
27	2	125 - 128	EtOAc	$C_{24}H_{31}ClN_4O_7$	$77^{s}/64^{h}$	7.2	6.0	16
28	2	123-124	Et_2O	$C_{23}H_{30}CIN_{3}O_{6}$	62	7.6	6.9	5
29	2	8788	Et_2O	$C_{25}H_{34}ClN_3O_7$	41	8.3	7.5	6
30	2	93-99	EtOAc	$C_{24}H_{33}ClN_4O_6$	40	7.0	7.0	1
32	2	124-126	EtOAc	$C_{23}H_{30}CIN_3O_6$	59	8.0	7.2	6
33	2	79-81	MeOH	C ₂₄ H ₃₂ ClN ₃ O ₆ ·H ₂ O	9	8.5	7.6	8
nifedi	ipine				8.4	7.5	8	

^aNegative logarithm of the molar concentration required to block Ca²⁺-induced contraction of K⁺-depolarized rat aorta by 50%. Nifedipine was used as the standard compound, standard deviation ± 0.01 . ^bNegative logarithm of the molar concentration required to depress contraction in the Langendorff perfused guinea pig heart by 25%. Nifedipine was used as the standard compound, standard deviation ± 0.26 . ^cSelectivity index = IC₅₀(Ca²⁺)/IC₂₅(negative inotropy). ^dn = 2 (± 0.3). ^eYield obtained from alkylation of 1 with 1.1 equiv of chloroacetamide. ^fYield obtained from reaction of 24 with concentrated aqueous ammonia. ^gYield obtained from alkylation of 1 with 2.7 equiv of chloroacetamide. ^hYield obtained from reaction of 25 with concentrated aqueous ammonia.





^aReagents: (a) BrCH₂CO₂CH₃, K₂CO₃, heat; (b) ClCH₂CONH₂, K₂CO₃, heat; (c) concentrated aqueous ammonia; (d) RNH₂; (e) BrCH(CH₃)CO₂Et, K₂CO₃, heat; (f) BrC(CH₃)₂CONH₂, K₂CO₃, heat.



center is tolerated.¹ It is also apparent that alkyl substitution on the nitrogen atom causes a reduction in activity in 9, 17, and 21, as exemplified by 10, 18, and 22.

From the data for the glycinamide derivatives (26-33), it is apparent that the presence of both a basic center and a polar, nonbasic amide group is compatible with good calcium antagonist potency. The tolerance of the DHP receptor to the presence of bulky substituents on the 2position of the DHP ring is reflected by the fact that 26 is equipotent with nifedipine. The in vitro activity seen for 33 and 29 demonstrates that neither substituent of the methylene adjacent to the carboxamide group nor the introduction of substituents on the amide group, respectively, have any significant effect on calcium antagonist activity. However, in parallel with the observations above, both 30, in which the carboxamide substituent contains a second basic center, and 27, in which the nitrogen attached to the ethoxymethyl chain is disubstituted, are markedly less potent than 26.

It is now generally accepted that the voltage-dependent calcium channel can exist in one of three states (open, resting, and inactivated) and that DHP antagonists bind preferentially^{10,11} to the inactivated state. Because the inactivated state is favored by increasingly negative resting potentials, DHPs would thus be expected to be intrinsically more effective in smooth-muscle tissue than cardiac tissue, since the latter normally exhibits a more negative resting potential and undergoes only brief periods of depolarization during the cardiac cycle. This reasoning has been put forward¹² to account for the apparent inherent selectivity of DHPs for vascular over cardiac tissue. In support of this view is the observation that amlodipine and nifedipine, which have structurally, sterically, and physicochemically different substituents on the DHP 2-position, exhibit similar (ca. 10-fold) selectivity for vascular over cardiac tissue.¹ However, an examination of the data in Table I reveals that tissue selectivity is also dependent on structure, at least to some degree. Thus, while many of the compounds have the same selectivity index as nifedipine,

- (10) Sanguinetti, M. C.; Kass, R. S. Circ. Res. 1984, 55, 336.
- (11) Bean, B. P. Proc. Natl. Acad. Sci. U.S.A. 1984, 81, 6388.
- (12) Godfraind, T.; Morel, N.; Wibo, J. Trends Pharm. Sci. 1988, 9, 37.

Table II. Coronary Vasodilator Activity for 10, 11, 26, 32, 33, and Nifedipine in Anesthetized Dogs following Intravenous Administration (150 μ g kg⁻¹)

compound	percentage decrease in CVR	duration of action, ^a min
10	68	15
11	61	15
26	88	>300
32	73	150
33	85	210
nifedipine	77	36

^aTime taken for 50% recovery of CVR.

certain derivatives are markedly more or less selective. In general, the most highly tissue-selective compounds 7, 14, 16, 26, and 27 contain an amide group at the terminus of the 2-substituent. However, in contrast to amlodipine,¹ the presence of a basic center at the terminus of the 2substituent as in 13, 23, and 30 causes a loss of selectivity for vascular over cardiac tissue. Remarkably urea 15 exhibits "reversed" selectivity, being some 10-fold more active on cardiac tissue. Literature evidence is also available which demonstrates that DHPs can exhibit a range of tissue selectivities. Thus, it has been reported that nisoldipine shows vascular selectivity 100 times that seen for nifedipine¹³ while it has recently been claimed¹⁴ that certain halogenated derivatives of nitrendipine are 10-fold more vascular selective than nitrendipine itself.

The mechanism by which the presence of certain structural features in DHPs alters the tissue selectivity is not fully understood. It has been suggested^{13,15} that increased potency per se leads to more pronounced selectivity. However, this is not entirely the case for the compounds in Table I since the pairs of compounds 4 and 16 and 6 and 27 have equivalent IC_{50} 's on vascular tissue but exhibit markedly different selectivities. It has also been suggested¹⁴ that improved vascular selectivity may at least in part be a consequence of differences in lipophilicity. We believe that the differences in selectivity index seen for the compounds in Table I cannot be explained simply on the grounds of potency or overall lipophilicity and that structural differences in the 2-substituent lead directly to variations in selectivity between vascular and cardiac tissue. Two possible mechanistic explanations for this phenomenon can be advanced. Firstly, it is possible that DHP binding to the inactivated state of the channel^{10,11} may not be exclusive; a higher degree of open-state binding by certain derivatives would lead to relatively higher affinity for the cardiac channel, and thus reduced vascular selectivity. Alternatively, by analogy with the well-described heterogeneity of hormone receptors into subtypes with different primary protein structures, it may be that similar structural differences exist for the DHP-sensitive calcium channels in vascular and cardiac tissues. While the primary sequences of the various subunits of the calcium channel have now been established,¹⁶ the location and sequence of the DHP binding site has yet to be elucidated. Further advances are thus required in order to fully understand the reasons for variation in tissue selectivity among DHPs.

Table III. Pharmacokinetic Data for Compound **26** in Comparison with Felodipine¹⁹ and Amlodipine¹ in Dogs after Intravenous Administration

compound	plasma clearance, mL min ⁻¹ kg ⁻¹	vol of distribution, L kg ⁻¹	plasma half-life, h
26	7.0	3.0	4.7
felodipine	38	3.6	1.0
amlodipine	11	25	30

On the basis of their potency and selectivity, compounds 10, 11, 26, 32, and 33 were selected for in vivo evaluation in instrumented, anesthetized dogs. These compounds were administered intravenously and their calcium antagonist potency and duration of action were determined from the effects on coronary vascular resistance (CVR). As might be expected on the basis of their in vitro activity. all compounds were of similar potency to nifedipine and produced maximum or near-maximum falls in CVR at a dose of 150 μ g kg⁻¹ (Table II). However, there were significant differences in the durations of action of the compounds examined. The effect of 10 and 11 on CVR was relatively short-lived, while 26, 32, and 33, which all contain a basic center, had markedly longer durations of action than nifedipine. The duration of action of 26 was particularly noteworthy, being over 5 h. These results illustrate that the presence of a basic center in the 2-substituent on the DHP ring has a beneficial effect on duration of action, as might be expected from SAR studies with amlodipine.

In order to clarify these observations, a pharmacokinetic study in dogs was performed on 26. Compound 26 has an elimination half-life of 4.7 h (Table III), which is consistent with its duration of action in the anesthetized dog (Table II). Thus, the compound has a markedly longer half-life than felodipine, although its half-life is much shorter than that of amlodipine. Amlodipine and 26 have similar plasma clearance values, which are each significantly lower than that of felodipine. Although other factors may also be important, it is possible that the extended 2-substituent present in both 26 and amlodipine hinders their binding to the cytochrome p450 enzymes responsible for metabolic oxidation of DHPs to the corresponding pyridines,¹⁷ thereby reducing plasma clearance.

The shorter half-life of 26 compared to that of amlodipine is a consequence of its much lower volume of distribution, which is approximately equal to that seen for felodipine. Amlodipine has a remarkably large volume of distribution¹ and a hypothesis to explain this phenomenon has recently been proposed.¹⁸ Thus, it has been suggested from the results of X-ray diffraction studies that the position adopted by amlodipine within biological membrane bilavers favors the existence of a charge-charge interaction between the protonated amino group on amlodipine and a region of negative charge in the phosphate head group of the membrane phospholipid. This interaction, which arises because of the discrete position of the basic center on the 2-substituent in amlodipine, is suggested to account for the high partition coefficient of amlodipine, as measured in biological membranes,¹⁸ and possibly the large volume of distribution observed in animals and man. Although 26 has a basic center in the same relative position as that in amlodipine, its much lower volume of distribution suggests that a charge-charge interaction within the membrane of the type proposed for

(19) Humphrey, M. J.; Stopher, D. A. Unpublished results.

⁽¹³⁾ Godfraind, T.; Egleme, C.; Finet, M.; Jaumin, P. Pharmacol. Toxicol. 1987, 61, 79.

⁽¹⁴⁾ Fricke, U.; Klaus, W.; Stein, B. Arch. Pharmacol. 1988, 338, 449.

⁽¹⁵⁾ Wibo, M.; DeRoth, L.; Godfraind, T. Circ. Res. 1988, 62, 91.

⁽¹⁶⁾ Ellis, S. B.; Williams, M. E.; Ways, N. R.; Brenner, R.; Sharp, A. H.; Leung, A. T.; Campbell, K. T.; McKenna, E.; Koch, W. J.; Hui, A.; Schwartz, A.; Harpold, M. M. Science 1988, 241, 1661.

⁽¹⁷⁾ Bocker, R. H.; Guengerich, F. P. J. Med. Chem. 1986, 29, 1596.

⁽¹⁸⁾ Mason, R. P.; Campbell, S. F.; Wang, S.; Herbette, L. G. Mol. Pharm. In press.

amlodipine is not as favorable for this compound. This may be a consequence of an unfavorable steric interaction between the carboxamidomethyl group in 26 and the phosphate head group of the membrane phospholipid. Alternatively, the lower pK_a of 26 compared to that of amlodipine may reduce the charge-charge interaction between the protonated amino group of 26 and the phosphate head group.

In conclusion, we have established that the incorporation of polar, nonbasic, acyclic substituents on the 2-position of the DHP ring can give compounds which exhibit calcium antagonist activity equivalent to that seen for nifedipine. In addition we have shown that combining the basic center of amlodipine with amide groups gives potent calcium antagonists with good selectivity for vascular tissue over cardiac tissue. One of these compounds, **26** (UK-51,656) has a duration of action in excess of 5 h on intravenous administration to an anesthetized dog and its pharmacokinetic half-life was shown to be markedly longer than that of felodipine.

Experimental Section

Pharmacology. In vitro calcium antagonism IC_{50} and negative inotropy IC_{25} were measured as previously described.¹

In vivo hemodynamic measurements were made in anesthetized beagle dogs implanted with catheters for the measurement of blood pressure and left ventricular pressure and for the intravenous administration of test compound. Coronary blood flow was measured by the hydrogen-clearance technique using platinum electrodes positioned in the coronary sinus and femoral artery as reported in the literature.²⁰ Cardiac output was determined by the thermodilution method. All other parameters were derived from these measurements. Compound was administered as one single dose to assess duration of action.

Chemistry. All melting points are uncorrected. The structures of all the compounds were determined by ¹H NMR spectroscopy and microanalysis. Microanalytical data were not obtained for intermediates 11, 20, and 24. However, the ¹H NMR spectrum of each of these compounds was wholly compatible with its proposed structure and TLC data established the purity of each compound. ¹H NMR spectra were obtained with a Varian XL-100-5 spectrometer using CDCl₃ as the solvent.

All compounds were obtained as racemic mixtures. The preparation of amines 1 and 8 has been described in a previous publication.¹ The preparation of S-methylisothiourea 19 has also been reported.⁶ S-Methylisothiourea 20 was prepared in a directly analogous manner by reacting 8 with N-cyanoimidodithio-carbonate.

2-[[2-(N-Acetylamino)ethoxy]methyl]-4-(2-chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6methyl-1,4-dihydropyridine (4). CH₃COCl (0.22 g, 3.0 mmol) was added dropwise to a stirred, ice-cooled solution of 1 (0.82 g, 2.0 mmol) in pyridine (5 mL), and the mixture was stirred at room temperature for 14 h, poured into 2 M HCl, and extracted with EtOAc. The EtOAc extract was washed successively with 2 M HCl and water, dried over Na₂SO₄, and evaporated. The residue was purified by chromatography on SiO₂ using CH₂Cl₂ plus 0-5% MeOH as eluant. Appropriate fractions were combined and evaporated, and the residue crystallized from Et₂O to give title compound 4: yield 0.68 g (75%); mp 97-99 °C. Anal. (C₂₂-H₂₇ClN₂O₆)C, H, N.

General Route to Amides (5-7). 4-Methylmorpholine was added dropwise to a stirred, ice-cooled mixture of 1, 1-[(3-dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride, 1hydroxybenzotriazole hydrate, and the appropriate carboxylic acid in CH₂Cl₂. The mixture was stirred at room temperature for 16 h, diluted with CH₂Cl₂, washed successively with water, 2 M HCl, water, 10% aqueous Na₂CO₃ solution and water, dried over Na₂SO₄, and evaporated. The residue was purified by chromatography on SiO₂ using CH₂Cl₂ plus 0-5% MeOH as eluant. Appropriate fractions were combined and evaporated, and the residue was crystallized from Et₂O.

4-(2-Chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-2-[[2-[N-(3-pyridylcarbonyl)amino]ethoxy]methyl]-1,4-dihydropyridine (5). Addition of 4methylmorpholine (0.61 g, 6.0 mmol) to a mixture of 1 (0.4 g, 1.0 mmol), 1-[(3-dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (0.42 g, 2.2 mmol), 1-hydroxybenzotriazole hydrate (0.17 g, 1.1 mmol), and nicotinic acid (0.14 g, 1.1 mmol) in CH₂Cl₂ (40 mL) followed by workup as described above gave title compound 5: yield 0.29 g (57%); mp 81-84 °C. Anal. (C₂₈H₂₈ClN₃O₆) C, H, N.

4-(2-Chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-2-[[2-[N-(2-pyrazinylcarbonyl)amino]ethoxy]methyl]-1,4-dihydropyridine (6). Addition of 4methylmorpholine (1.22 g, 12.0 mmol) to a mixture of 1 (0.82 g, 2.0 mmol), 1-[(3-dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (0.84 g, 4.4 mmol), 1-hydroxybenzotriazole hydrate (0.34 g, 2.2 mmol), and pyrazine-2-carboxylic acid (0.28 g, 2.2 mmol) in CH₂Cl₂ (80 mL) followed by workup as described above gave the title compound 6: yield 0.46 g (42%); mp 117–118 °C. Anal. (C₂₅H₂₇ClN₄O₆) C, H, N.

4-(2-Chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-2-[[2-[N-(pyrid-6-on-3-ylcarbonyl)amino]ethoxy]methyl]-1,4-dihydropyridine (7). Addition of 4-methylmorpholine (0.91 g, 9.0 mmol) to a mixture of 1 (0.82 g, 2.0 mmol), 1-[(3-dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (0.84 g, 4.5 mmol), 1-hydroxybenzotriazole hydrate (0.3 g, 2.2 mmol), and 6-hydroxypyridine-3-carboxylic acid (0.28 g, 2.0 mmol) in CH₂Cl₂ (40 mL) followed by workup as described above gave title compound 7: yield 0.68 g (63%); mp 125-130 °C dec. Anal. (C₂₈H₂₈ClN₃O₇) C, H, N.

1-[2-[[4-(2-Chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyrid-2-yl]methoxy]ethyl]-3-methylurea (9). MeNCO (0.5 mL) was added to a solution of 1 (0.41 g, 1.0 mmol) in CH_2Cl_2 (50 mL) and the mixture stirred at room temperature for 2 h and evaporated. The residue was crystallized from Et₂O to give title compound 9: yield 0.40 g (85%); mp 75-90 °C dec. Anal. ($C_{22}H_{28}ClN_3O_6$) C, H, N.

1-[2-[[4-(2-Chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyrid-2-yl]methoxy]ethyl]-1,3-dimethylurea (10). MeNCO (100 mg, 1.45 mmol) was added to a solution of 8 (200 mg, 0.47 mmol) in CH₂Cl₂ (8 mL) and the mixture was stirred at room temperature for 2 h and evaporated. The residue was purified by chromatography on SiO₂ using CH₂Cl₂ plus 0–10% EtOAc as eluant. Appropriate fractions were combined and evaporated, and the residue was crystallized from Et₂O/EtOAc to give title compound 10: yield 120 mg (53%); mp 160–162 °C. Anal. (C₂₃H₃₀ClN₃O₆) C, H, N.

1-[2-[[4-(2-Chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyrid-2-yl]methoxy]ethyl]-3-[(ethoxycarbonyl)methyl]urea (11). A solution of 1 (0.41 g, 1.0 mmol) and (ethoxycarbonyl)methyl isocyanate (0.30 mL) in acetonitrile (5 mL) was heated under reflux for 2.5 h and evaporated. The residue was triturated with Et₂O and the resulting solid was collected, dried, and recrystallized from Et-OAc/hexane to give title compound 11: yield 220 mg (86%); mp 125-127 °C; ¹H NMR (CDCl₃) $\delta = 6.85-7.55$ (5 H, m), 5.35 (1 H, s), 5.2-5.6 (1 H, br s), 4.64 (2 H, s), 4.10 (2 H, q, J = 7 Hz), 3.93 (2 H, q, J = 5 Hz), 3.88 (2 H, q, J = 7 Hz), 3.53 (3 H, s), 3.2-3.6 (4 H, m), 2.28 (3 H, s), 1.20 (3 H, t, J = 7 Hz), and 1.09 (3 H, t, J = 7 Hz).

4-(2-Chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-2-[[(1-imidazolyl)carbonyl]amino]-6-methyl-1,4dihydropyridine (12). A solution of 1 (20.49 g, 50 mmol) in THF (150 mL) was added dropwise over 45 min to a stirred solution of CDI (8.9 g, 54 mmol) and 4-methylmorpholine (20 mL) in THF (350 mL) and the mixture was stirred at room temperature for 2 h and evaporated. The residue was partitioned between EtOAc and water and the organic layer was washed with water, dried over Na₂SO₄, and evaporated. The residue was crystallized from Et₂O to give title compound 12: yield 16.6 g (66%); mp 149–151 °C. Anal. (C₂₄H₂₇ClN₄O₆) C, H, N.

General Route to Ureas 13–16. A mixture of 12 (0.98 g, 2.0 mmol) and the appropriate amine in CH_3CN (10 mL) was stirred at room temperature for 16 h and then evaporated. The residue

was purified by chromatography on SiO₂ using CH_2Cl_2 plus 0-3% MeOH as eluant. Appropriate fractions were combined and evaporated.

3-(2-Aminoethyl)-1-[2-[[4-(2-chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyrid-2-yl]methoxy]ethyl]urea (13). Reacting 12 with 1,2-diaminoethane (120 mg, 2.0 mmol) and workup as described above gave the title compound 13 as a colorless oil: yield 0.56 g (58%). A portion of this oil was converted to an analytically pure maleate salt by treatment with 1 equiv of maleic acid in EtOAc and recrystallization of the resulting solid from EtOAc/EtOH: mp 90 °C dec. Anal. ($C_{23}H_{31}ClN_4O_6\cdot C_4H_4O_4$)C; H: calcd, 5.81; found, 6.31; N.

3-[(Aminocarbonyl)methyl]-1-[2-[[4-(2-chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyrid-2-yl]methoxy]ethyl]urea (14). Reacting 12 with glycinamide (0.22 g, 3.0 mmol) and workup as described above gave, after crystallization of the residue from EtOAc, title compound 14: yield 0.25 g (23%); mp 114-116 °C. Anal. ($C_{23}H_{29}$ -ClN₄O₇) C, H, N.

1-[2-[[4-(2-Chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyrid-2-yl]methoxy]ethyl]-3-(2-hydroxy-4-pyrimidinyl)urea (15). Reacting 12 with 4-amino-2-hydroxypyrimidine (0.22 g, 2.0 mmol) and workup as described above gave, after crystallization of the residue from EtOAc, title compound 15: yield 0.18 g (16%); mp 140–143 °C. Anal. ($C_{25}H_{28}ClN_6O_5$:H₂O) C, H, N: calcd, 12.42; found, 11.84.

1-[2-[[4-(2-Chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyrid-2-yl]methoxy]ethyl]-3-[2-(2-oxoimidazolidin-1-yl)ethyl]urea (16). Reacting 12 with 1-(2-aminoethyl)imidazolidin-2-one (0.26 g, 2.0 mmol) and workup as described above gave, after crystallization from EtOAc, title compound 16: yield 0.355 g (32%); mp 75-77 °C. Anal. ($C_{26}H_{34}ClN_5O_7$) C, H; N: calcd, 12.42; found, 11.50.

1-[2-[[4-(2-Chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyrid-2-yl]methoxy]ethyl]sulfamide (17). A solution of 1 (0.82 g, 2.0 mmol) and sulfamide (0.96 g, 10 mmol) in dioxane (30 mL) was heated under reflux for 70 min and evaporated. The residue was partitioned between EtOAc and water, and the organic layer was dried over Na₂SO₄ and evaporated. The residue was crystallized from Et₂O to give title compound 17: yield 0.75 g (77%); mp 150-152 °C. Anal. ($C_{20}H_{26}ClN_3O_7S$) C, H, N.

1-[2-[[4-(2-Chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyrid-2-yl]methoxy]ethyl]-1-methylsulfamide (18). A solution of 8 (0.42 g, 1.0 mmol) and sulfamide (0.96 g, 10 mmol) in dioxane (40 mL) was heated under reflux for 2 h, diluted with CH_2Cl_2 (100 mL), washed with water, dried over Na_2SO_4 , and evaporated. The residue was crystallized from Et_2O to give title compound 18: yield 0.44 g (88%); mp 117-120 °C. Anal. ($C_{21}H_{28}ClN_3O_7S$) C, H, N.

1-[2-[[4-(2-Chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyrid-2-yl]methoxy]ethyl]-3-cyano-2-methylisothiourea (20): 87% yield; foam.

1-[2-[[4-(2-Chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyrid-2-yl]methoxy]ethyl]-2-cyano-3-methylguanidine (21). A suspension of 19 (0.40 g, 0.8 mmol) in 33% ethanolic methylamine (10 mL) was stirred at room temperature for 18 h and evaporated. The residue was crystallized from EtOH to give title compound 21: yield 0.25 g (64%); mp 188-190 °C. Anal. ($C_{23}H_{28}CIN_5O_5$) C, H, N.

1-[2-[[4-(2-Chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyrid-2-yl]methoxy]ethyl]-2-cyano-1,3-dimethylguanidine (22). A solution of 20 (0.64 g, 1.2 mmol) in 33% ethanolic methylamine (25 mL) was stirred at room temperature for 30 min and evaporated. The residue was taken up in toluene, evaporated, and purified by chromatography on SiO₂ using CH₂Cl₂ plus 0-5% MeOH as eluant. Appropriate fractions were combined and evaporated and the residue was crystallized from Et₂O to give title compound 22: yield 0.46 g (74%); mp 131-136 °C. Anal. ($C_{24}H_{30}$ ClN₅O₅) C, H, N.

1-[2-[[4-(2-Chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyrid-2-yl]methoxy]ethyl]-2-cyano-3-[2-(dimethylamino)ethyl]guanidine (23). A mixture of 19 (0.35 g, 0.7 mmol) and 2-(dimethylamino)ethylamine (5 mL) was heated at 95 °C for 1.5 h and evaporated. The residue was crystallized from EtOAc to give title compound 23: yield 0.30 g (79%); mp 202–204 °C dec. Anal. ($C_{26}H_{35}ClN_6O_5$) C, H, N.

4-(2-Chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-2-[[2-[N-[(methoxycarbonyl)methyl]amino]ethoxy]methyl]-6-methyl-1,4-dihydropyridine (24) and 2-[[2-[N,N-Bis[(methoxycarbonyl)methyl]amino]ethoxy]methyl]-4-(2-chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyridine (25). A mixture of 1 (4.08 g, 10 mmol), methyl bromoacetate (1.53 g, 10 mmol), and K₂CO₃ (2.76 g, 20 mmol) in CH₃CN (100 mL) was heated under reflux for 2 h, filtered, and evaporated. The residue was partitioned between CH₂Cl₂ and water, and the organic layer was dried over MgSO₄ and evaporated. The residue was chromatographed on SiO₂ using CH₂Cl₂ plus 0-2% MeOH as eluant. In each case, appropriate fractions were combined and evaporated to give the title compounds. 24 (more polar compound): yield, 1.50 g (31%); oil. Anal. (C23H29ClN2O7) C, H, N. 25 (less polar compound): yield 1.45 g (30%); mp 40 °C. Anal. (C₂₆H₃₃N₂O₉) C. H. N

2-[[2-[N,N-Bis] (aminocarbonyl)methyl]amino]ethoxy]methyl]-4-(2-chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyridine (27). A solution of 25 (1.32 g, 2.5 mmol) and concentrated aqueous ammonia (30 mL) in MeOH (15 mL) was stirred at room temperature for 2 h and evaporated. The residue was partitioned between EtOAc and water, and the organic layer was dried over Na₂SO₄ and evaporated. The residue was purified by chromatography on SiO₂ using CH_2Cl_2 plus 0-10% MeOH as eluant. Appropriate fractions were combined and evaporated, and the residue was crystallized from EtOAc to give title compound 27: yield 0.80 g (64%); mp 125-128 °C. Anal. ($C_{24}H_{31}ClN_4O_7$) C: calcd, 55.12; found, 54.37; H, N.

Reaction of 1 with 2-Chloroacetamide. A mixture of 1 (2.04 g, 5.0 mmol), 2-chloroacetamide (0.50 g, 5.5 mmol), and K_2CO_3 (1.36 g, 10 mmol) in acetonitrile (80 mL) was heated under reflux for 14 h, filtered, and evaporated. The residue was partitioned between CH_2Cl_2 and water, and the organic layer was dried over Na_2SO_4 and evaporated. The residue was chromatographed on SiO_2 using CH_2Cl_2 plus 0–10% MeOH as eluant. Appropriate fractions were combined and evaporated to give 26: yield 0.71 g (31%). A second product whose TLC characteristics were identical with those of 27 was also isolated from this reaction.

A mixture of 1 (0.41 g, 2.7 mmol), 2-chloroacetamide (0.25 g, 2.7 mmol), and K_2CO_3 (0.42 g, 3 mmol) in DMF (20 mL) was heated at 115 °C for 4 h, filtered, and evaporated. The residue was worked up and purified as described above to give 27: yield 0.40 g (77%). A small amount of product whose TLC characteristics were identical with those of 26 was also isolated from this reaction.

2-[[2-[[4-(2-Chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyrid-2-yl]methoxy]-ethyl]amino]-N-methylacetamide (28). A mixture of 24 (0.39 g, 0.80 mmol) and 40% aqueous methylamine solution (5 mL) in MeOH (10 mL) was stirred at room temperature for 3 days and evaporated. The residue was partitioned between EtOAc and water, and the organic layer was washed with water, dried over Na₂SO₄, and evaporated. The residue was purified by chromatography on SiO₂ using CH₂Cl₂ plus 0-5% MeOH as eluant. Appropriate fractions were combined and evaporated, and the residue was crystallized from Et₂O to give title compound 28: yield 0.24 g (62%); mp 123-124 °C. Anal. ($C_{23}H_{30}ClN_3O_6$) C, H, N.

2-[[2-[[4-(2-Chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyrid-2-yl]methoxy]ethyl]amino]-N-(2-methoxyethyl)acetamide (29). A solution of 24 (0.39 g, 0.8 mmol) and 2-methoxyethylamine (5 mL) in MeOH (10 mL) was stirred at room temperature for 18 h and evaporated. The residue was partitioned between EtOAc and water, and the organic layer was washed with water, dried over Na₂SO₄, and evaporated. The residue was purified by chromatography on SiO₂ using CH₂Cl₂ plus 0–5% MeOH as eluant. Appropriate fractions were combined and evaporated, and the residue was crystallized from Et₂O to give title compound **29**: yield 0.17 g (41%); mp 87–88 °C. Anal. (C₂₅H₃₄ClN₃O₇) C, H, N.

N-(2-Aminoethyl)-2-[[2-[[4-(2-chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyrid-2-yl]methoxy]ethyl]amino]acetamide (30). A solution of 24 (0.58 g, 1.2 mmol) and 1,2-diaminoethane (5 mL) in MeOH (10 mL) was stirred at room temperature for 18 h and evaporated. The residue was partitioned between EtOAc and water, and the organic layer was washed with water, dried over Na₂SO₄, and evaporated. The residue was purified by chromatography on SiO₂ using CH₂Cl₂ plus 10–30% MeOH as eluant. Appropriate fractions were combined and evaporated, and the residue was crystallized from EtOAc to give title compound 30: yield 0.16 g (40%); mp 93–99 °C. Anal. (C₂₄H₃₃ClN₄O₆)C: calcd, 56.63; found, 56.00; H, N.

Ethyl 2-[[2-[[4-(2-Chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyrid-2-yl]methoxy]ethyl]amino]propionate (31). A mixture of 1 (4.08 g, 10 mmol), ethyl 2-bromopropionate (2.00 g, 11 mmol), and K_2CO_3 (2.8 g, 20 mmol) in acetonitrile (120 mL) was heated under reflux for 24 h, filtered, and evaporated. The residue was partitioned between EtOAc and water, and the organic layer washed with water, dried over Na₂SO₄, and evaporated. The residue was purified by chromatography on SiO₂ using CH₂Cl₂ plus 0-2% MeOH as eluant. Appropriate fractions were combined and evaporated, and the residue was crystallized from Et₂O to give title compound 31: yield 1.40 g (28%); mp 89-90 °C. Anal. (C₂₈H₃₃ClN₂O₇) C, H, N.

2-[[2-[[4-(2-Chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyrid-2-yl]methoxy]ethyl]amino]propionamide (32). A solution of 31 (1.02 g, 2.0 mmol) and concentrated aqueous ammonia (25 mL) in EtOH (30 mL) was stirred at room temperature for 14 days and evaporated. The residue was partitioned between EtOAc and water, and the organic layer was washed with water, dried over Na₂SO₄, and evaporated. The residue was purified by chromatography on SiO₂ using CH₂Cl₂ plus 0–5% MeOH as eluant. Appropriate fractions were combined and evaporated, and the residue was crystallized from EtOAc to give title compound **32**: yield 0.56 g (59%); mp 124–126 °C. Anal. ($C_{23}H_{30}ClN_3O_6$) C, H, N.

2-[[2-[[4-(2-Chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyrid-2-yl]methoxy]ethyl]amino]-2-methylpropionamide (33). A mixture of 1 (4.08 g, 10 mmol), 2-bromo-2-methylpropionamide (1.66 g, 10 mmol), and K_2CO_3 (2.07 g, 15 mmol) in CH₃CN (50 mL) was heated under reflux for 18 h, filtered, and evaporated. The residue was partitioned between EtOAc and water, and the organic layer was washed with water, dried over Na₂SO₄, and evaporated. The residue was purified by chromatography on SiO₂ using CH₂Cl₂ plus 0-5% MeOH as eluant. Appropriate fractions were combined and evaporated, and the residue was crystallized from MeOH to give title compound 33: yield 0.45 g (9%); mp 79-81 °C. Anal. ($C_{24}H_{32}ClN_3O_6\cdot H_2O)C$: calcd, 56.30; found, 56.89; H, N.

Acknowledgment. We thank J. A. Morris and S. F. Tickner for their able technical assistance, J. K. Stubbs for the synthesis of 10 and 11, and D. A. Stopher and M. J. Humphrey for performing the pharmacokinetics on 26, 33, and felodipine. We are also grateful to P. J. Wadsworth and his staff for analytical and spectral data.

Registry No. 1, 88150-42-9; 4, 123700-09-4; 5, 123700-10-7; 6, 123700-11-8; 7, 123700-12-9; 8, 103069-16-5; 9, 123700-13-0; 10, 123700-14-1; 11, 123700-15-2; 12, 123700-16-3; 13, 123700-17-4; 13-maleate, 123700-18-5; 14, 123700-19-6; 15, 123700-20-9; 16, 123700-21-0; 17, 123700-22-1; 18, 123700-23-2; 19, 123700-24-3; 20, 123700-25-4; 21, 123700-26-5; 22, 123700-27-6; 23, 123700-28-7; 24, 123700-29-8; 25, 123700-30-1; 26, 123700-31-2; 27, 123700-32-3; 28, 123700-33-4; 29, 123700-34-5; 30, 123700-35-6; 31, 123700-36-7; 32, 123700-37-8; 33, 123700-38-9; EtO2CCH2NCO, 2949-22-6; H2NCH2CH2NH2, 107-15-3; H2NCH2CONH2, 598-41-4; NH2S-O₂NH₂, 7803-58-9; MeOCH₂CH₂NH₂, 109-85-3; H₃CCH(Br)CO₂Et, 41978-69-2; nicotinic acid, 59-67-6; 2-pyrazinecarboxylic acid, 98-97-5; 6-hydroxypyrazine-3-carboxylic acid, 5006-66-6; 4amino-2-hydroxypyrimidine, 71-30-7; 1-(2-aminoethyl)imidazolidin-2-one, 6281-42-1; 2-bromo-2-methylpropionamide, 7462-74-0.

Novel Glutamic Acid Derived Cholecystokinin Receptor Ligands

R. M. Freidinger,* W. L. Whitter, N. P. Gould, M. K. Holloway, R. S. L. Chang, and V. J. Lotti

Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania 19486. Received May 11, 1989

Novel aryl amide analogues of glutamic acid dialkylamide have been synthesized to test for a possible structural analogy between glutamic acid and benzodiazepine CCK antagonists such as compounds 2 and 24 (lorglumide and MK-329, respectively). In support of the structural model, certain of these hybrid compounds are more potent in pancreas CCK radioligand binding assays than corresponding lorglumide-type reference compounds. Modifications previously found in the benzodiazepine antagonists to result in brain CCK/gastrin receptor selectivity were also incorporated to produce an aryl urea series of glutamic acid analogues. None of these compounds were brain CCK/gastrin selective; however, one was potent and selective in the pancreas binding assay. The model appears to be most useful in the design of selective ligands for the pancreas type CCK receptor.

Cholecystokinin (CCK) was originally discovered as a gastrointestinal peptide,¹ and more recently it has been implicated as a neurotransmitter or neuromodulator.² The effects of CCK on pancreatic secretions, gut motility, and satiety have been studied intensively.^{3,4} These and other actions are mediated by at least two CCK receptor sub-types termed CCK-A and CCK-B.⁵ The former receptor

is found primarily in tissue types such as pancreas, gall bladder, and colon, although isolated regions have been localized in the central nervous system (CNS).^{5,6} The CCK-A receptors in the pancreas have been shown to be linked to phosphatidylinositol turnover.⁷ The primary CCK receptor subtype in the CNS is CCK-B,⁸ which has

⁽¹⁾ Mutt, V.; Jorpes, J. E. Biochem. J. 1971, 125, 57.

⁽²⁾ Morley, J. E. Life Sci. 1982, 20, 479.

⁽³⁾ Mutt, V. In Gastrointestinal Hormones; Glass, G. B. J., Ed.; Raven: New York, 1980; pp 169-221.

⁽⁴⁾ Stacher, G. Psychoneuroendocrinology 1986, 13, 39.

⁽⁵⁾ Moran, T. H.; Robinson, P.; Goldrich, M. S.; McHugh, P. Brain Res. 1986, 362, 175.

⁽⁶⁾ Hill, D. R.; Campbell, J. N.; Shaw, T. M.; Woodruff, G. N. J. Neurosci. 1987, 7, 2967.

⁽⁷⁾ Schnefel, S.; Banfic, H.; Eckhardt, L.; Schultz, G.; Schulz, I. FEBS Lett. 1988, 230, 125.